PMID- 23030524
OWN - NLM
STAT- MEDLINE
DCOM- 20130111
LR  - 20211021
IS  - 1600-0463 (Electronic)
IS  - 0903-4641 (Print)
IS  - 0903-4641 (Linking)
VI  - 120
IP  - 12
DP  - 2012 Dec
TI  - Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain 
      reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin 
      embedded tissue from 40 women with ovarian cancer.
PG  - 1000-7
LID - 10.1111/j.1600-0463.2012.02929.x [doi]
AB  - We compare HER2 receptor amplification analysis by immunohistochemistry (IHC), 
      fluorescence in situ hybridization (FISH), and real-time polymerase chain 
      reaction (real-time PCR) DNA copy-number assay following laser capture 
      microdissection (LCM) in formalin-fixed paraffin embedded tissue from 40 women 
      with verified ovarian cancer. We speculate that LCM should result in a more 
      accurate assessment of HER2 amplification in our real-time PCR assay compared 
      with IHC and FISH. HER2 overexpression measured by IHC, FISH, or real-time PCR 
      was found in 5.0%, 5.0%, and 22.5%, respectively. HER2 negative results measured 
      by IHC, FISH, or real-time PCR were found in 95%, 92.5%, and 60.0%, respectively. 
      Analysis failed for IHC, FISH, or real-time PCR in 0%, 2.5%, or 17.5% of cases. 
      Concordance between IHC and FISH, IHC and real-time PCR, or FISH and real-time 
      PCR were 89.7%, 72.7%, or 78.1%, respectively. Only few ovarian cancer patients 
      were HER2 overexpressed measured by IHC or FISH and thus could be eligible for 
      antibody-based therapy with trastuzumab (Herceptin). Interestingly, we find an 
      increased number of HER2 positive patients by real-time PCR analysis on 
      microdissected cancer cells, suggesting a number of HER2 positive patients not 
      detected by current methods. Thus, the concept of quantitative measurement of 
      HER2 on microdissected cancer cells should be explored further.
CI  - (c) 2012 The Authors APMIS (c) 2012 APMIS.
FAU - Hillig, Thore
AU  - Hillig T
AD  - Department of Clinical Biochemistry, Hillerod Hospital University of Copenhagen, 
      3400 Hillerod, Denmark. Thill@noh.regionh.dk
FAU - Thode, Jorgen
AU  - Thode J
FAU - Breinholt, Marie F
AU  - Breinholt MF
FAU - Franzmann, Maria-Benedicte
AU  - Franzmann MB
FAU - Pedersen, Carsten
AU  - Pedersen C
FAU - Lund, Flemming
AU  - Lund F
FAU - Mygind, Henrik
AU  - Mygind H
FAU - Soletormos, Gyorgy
AU  - Soletormos G
FAU - Rudnicki, Martin
AU  - Rudnicki M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120626
PL  - Denmark
TA  - APMIS
JT  - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
JID - 8803400
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Female
MH  - *Gene Amplification
MH  - Gene Dosage
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Laser Capture Microdissection
MH  - Ovarian Neoplasms/*genetics
MH  - Paraffin Embedding
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, ErbB-2/biosynthesis/*genetics
MH  - Trastuzumab
MH  - Tumor Cells, Cultured
PMC - PMC3533780
EDAT- 2012/10/04 06:00
MHDA- 2013/01/12 06:00
CRDT- 2012/10/04 06:00
PHST- 2012/02/17 00:00 [received]
PHST- 2012/05/07 00:00 [accepted]
PHST- 2012/10/04 06:00 [entrez]
PHST- 2012/10/04 06:00 [pubmed]
PHST- 2013/01/12 06:00 [medline]
AID - 10.1111/j.1600-0463.2012.02929.x [doi]
PST - ppublish
SO  - APMIS. 2012 Dec;120(12):1000-7. doi: 10.1111/j.1600-0463.2012.02929.x. Epub 2012 
      Jun 26.